Business Wire

L&T-TECHNOLOGY

15.3.2024 04:16:26 CET | Business Wire | Press release

Share
L&T Technology Services (LTTS) Secures Landmark ∼$100 Million Program in Cybersecurity

L&T Technology Services Limited (LTTS) (BSE: 540115, NSE: LTTS), a leading global pure-play engineering and technology services company, announced today that it has won a first-of-its-kind program in India worth around $100 million from Maharashtra State Cyber Department, under the Government of Maharashtra. This initiative extends LTTS’ commitment to developing secure, digitally interconnected smart and safe cities through premier Cyber Security and Digital Forensic solutions consolidated under one umbrella.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240314467779/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

First-of-its-kind program in India entails designing a sophisticated cybersecurity system using AI & Digital Forensic tools. (Photo: Business Wire)

In this pioneering initiative by the Government of Maharashtra, LTTS in consortium with M/s KPMG Assurance and Consulting Services LLP as forensics partner will provide advanced Cyber Security Solutions for the State enhancing public safety against cyber threats.

The project entails designing a sophisticated cybersecurity system and establishing a state-of-the-art, fully equipped, Cyber security and Cybercrime prevention Centre to address Cybercrime Incidents and Investigations by leveraging AI and Digital Forensic tools. The program also encompasses the following:

  • A Digital Threat Analytics Centre (DTAC) paired with a Centre of Excellence (COE) that will equip the forensic team with cutting edge digital forensic tools including Deepfake detection, Mobile Malware forensics, IoT investigation, Network forensics, object detection supporting crypto & blockchain, Hardware & Embedded forensics, drone forensics, social media forensics, image enhancement, voice analysis labs, IMEI/CDR analysis, CCTV acquisition tools and computer forensics to streamline crime scene management, reduce timelines and improve the efficiency of cybercrime investigations.
  • A Central Emergency Response Team (CERT) to deal with incident response and investigation based on advanced cyber threat intelligence and analytics like APT detection and data breach, adversary intelligence from darknet, advanced malware analysis, proactive threat hunting and red teaming.
  • State-of-the-art Security Operations Centre (SOC) fortified by AI & ML technologies with a skilled cyber team to protect critical infrastructure. SOC handles Endpoint Detection & Response, SIEM, SOAR, UEBA, ZTNA, CASB, DLP, NAC, DNS Security, IDAM, and PAM solutions.

The integration of Smart World and Communication within LTTS has significantly amplified its capabilities, enabling the company to provide advanced engineering solutions for public cyber safety leveraging experience of setting up 25+ command centers. The successful execution of this project in India will pave the way for LTTS to extend these capabilities globally.

Commenting on the milestone win, Amit Chadha, CEO and Managing Director of L&T Technology Services, said, "This first-of-its-kind deal is more than just a business achievement for us. It’s an opportunity to leverage our experience in setting up over 25 command centers and recognizing the growing criticality of cybersecurity and the need to invest in advanced digital safeguard platforms and tools for the benefit of the larger society. This deal will set the stage for LTTS to scale its offerings for our global clientele.”

M/s KPMG Assurance and Consulting Services LLP., as LTTS' consortium partner, has played a critical role in this engagement. Yezdi Nagporewalla, Chief Executive Officer, KPMG in India, said, "We are truly proud to be part of this groundbreaking initiative. Collaborating with Maharashtra State Cyber Department and LTTS as a forensic services partner is a matter of pride for KPMG and it showcases our shared commitment to public safety by providing advanced cyber security solutions to counter cyber threats."

ABOUT L&T TECHNOLOGY SERVICES

L&T Technology Services Limited (LTTS) is a listed subsidiary of Larsen & Toubro Limited focused on Engineering and R&D (ER&D) services. We offer consultancy, design, development and testing services across the product and process development life cycle. Our customer base includes 69 Fortune 500 companies and 57 of the world’s top ER&D companies, across industrial products, medical devices, transportation, telecom & hi-tech, and the process industries. Headquartered in India, we have over 23,200 employees spread across 22 global design centers, 28 global sales offices and 105 innovation labs as of December 31, 2023. For more information, please visit https://www.LTTS.com/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240314467779/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye